Santen, Glaukos enter MicroShunt distribution agreement

Glaukos will be the exclusive distributor of Santen’s MicroShunt in the United States, the companies announced.

The multi-year distribution agreement stipulates that Glaukos will be responsible for sales and distribution of the device, pending U.S. approval, while Santen continues to hold responsibility for manufacturing, quality and safety controls, regulatory activities and post-approval marketing requirements. according to a press release.

A minimally invasive ab externo surgical device, the MicroShunt is designed to treat primary open-angle glaucoma and is currently being studied in an FDA pivotal trial for IOP reduction.

“Santen is very excited to partner with Glaukos, whose proven surgical glaucoma expertise and established distribution and sales infrastructure in the United States are unparalleled,” Shigeo Taniuchi, Santen president and chief operating officer, said in the release. “We strongly believe that this partnership will bring MicroShunt, if approved, to physicians and patients in the United States in the most timely, efficient and effective way possible.”

Financial details of the agreement were not disclosed.

Glaukos will be the exclusive distributor of Santen’s MicroShunt in the United States, the companies announced.

The multi-year distribution agreement stipulates that Glaukos will be responsible for sales and distribution of the device, pending U.S. approval, while Santen continues to hold responsibility for manufacturing, quality and safety controls, regulatory activities and post-approval marketing requirements. according to a press release.

A minimally invasive ab externo surgical device, the MicroShunt is designed to treat primary open-angle glaucoma and is currently being studied in an FDA pivotal trial for IOP reduction.

“Santen is very excited to partner with Glaukos, whose proven surgical glaucoma expertise and established distribution and sales infrastructure in the United States are unparalleled,” Shigeo Taniuchi, Santen president and chief operating officer, said in the release. “We strongly believe that this partnership will bring MicroShunt, if approved, to physicians and patients in the United States in the most timely, efficient and effective way possible.”

Financial details of the agreement were not disclosed.